These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25307803)

  • 1. Lanreotide autogel in acromegaly - a decade on.
    Kyriakakis N; Chau V; Lynch J; Orme SM; Murray RD
    Expert Opin Pharmacother; 2014 Dec; 15(18):2681-92. PubMed ID: 25307803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.
    Schopohl J; Strasburger CJ; Caird D; Badenhoop K; Beuschlein F; Droste M; Plöckinger U; Petersenn S;
    Exp Clin Endocrinol Diabetes; 2011 Mar; 119(3):156-62. PubMed ID: 21086246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
    Murray RD; Melmed S
    J Clin Endocrinol Metab; 2008 Aug; 93(8):2957-68. PubMed ID: 18477663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lanreotide Autogel: a review of its use in the management of acromegaly.
    Croxtall JD; Scott LJ
    Drugs; 2008; 68(5):711-23. PubMed ID: 18370450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium.
    Ciccarelli A; Daly A; Beckers A
    Treat Endocrinol; 2004; 3(2):77-81. PubMed ID: 15743103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on lanreotide Autogel in acromegaly.
    Croxtall JD; Scott LJ
    BioDrugs; 2008; 22(4):275-7. PubMed ID: 18611070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days.
    Bronstein M; Musolino N; Jallad R; Cendros JM; Ramis J; Obach R; Leselbaum A; Catus F
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):514-9. PubMed ID: 16268802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
    Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.
    Andries M; Glintborg D; Kvistborg A; Hagen C; Andersen M
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):473-80. PubMed ID: 17941902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
    Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
    J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.
    Giustina A; Mazziotti G; Cannavò S; Castello R; Arnaldi G; Bugari G; Cozzi R; Ferone D; Formenti AM; Gatti E; Grottoli S; Maffei P; Maffezzoni F; Montini M; Terzolo M; Ghigo E
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2454-2464. PubMed ID: 28419317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
    Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
    Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly.
    Tutuncu Y; Berker D; Isik S; Ozuguz U; Akbaba G; Kucukler FK; Aydin Y; Guler S
    Pituitary; 2012 Sep; 15(3):398-404. PubMed ID: 21863263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.
    Burness CB; Dhillon S; Keam SJ
    Drugs; 2014 Sep; 74(14):1673-91. PubMed ID: 25193626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.
    Alquraini H; Del Pilar Schneider M; Mirakhur B; Barkan A
    Pituitary; 2018 Jun; 21(3):283-289. PubMed ID: 29357081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
    An Z; Lei T; Duan L; Hu P; Gou Z; Zhang L; Durand-Gasselin L; Wang N; Wang Y; Gu F;
    BMC Endocr Disord; 2020 May; 20(1):57. PubMed ID: 32366244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.
    Neggers SJ; Pronin V; Balcere I; Lee MK; Rozhinskaya L; Bronstein MD; Gadelha MR; Maisonobe P; Sert C; van der Lely AJ;
    Eur J Endocrinol; 2015 Sep; 173(3):313-23. PubMed ID: 26047625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic evaluation of lanreotide.
    Hu M; Tomlinson B
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1301-12. PubMed ID: 20716034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.